Nektar Therapeutics (NKTR) Interest & Investment Income (2010 - 2026)

Nektar Therapeutics' Interest & Investment Income history runs 9 years deep, the most recent figure standing at $4.2 million for Q1 2026.

• On a quarterly basis, Interest & Investment Income rose 47.6% year-over-year to $4.2 million in Q1 2026; TTM through Mar 2026 was $11.8 million, a 10.25% decrease from a year earlier, with the FY2025 full-year figure at $10.4 million, down 28.01% from the prior year.
• Interest & Investment Income grew to $4.2 million in Q1 2026 per NKTR's latest filing, from $2.8 million in the prior quarter.
• Across five years, Interest & Investment Income topped out at $5.2 million in Q3 2023 and bottomed at $2.0 million in Q2 2025.
• The 4-year median for Interest & Investment Income is $3.9 million (2024), against an average of $3.7 million.
• Across the five-year window, Interest & Investment Income slumped 49.53% in 2025 and jumped 47.6% in 2026, its largest moves.
• Year by year, Interest & Investment Income stood at $4.6 million in 2023, then plunged by 36.28% to $2.9 million in 2024, then dropped by 5.64% to $2.8 million in 2025, then soared by 52.81% to $4.2 million in 2026.
• Per Business Quant, the three latest NKTR Interest & Investment Income figures stand at $4.2 million (Q1 2026), $2.8 million (Q4 2025), and $2.8 million (Q3 2025).